Dataset Viewer
text
stringlengths 1
194
|
|---|
detection, elimination (PARADE): a position paper of the |
30.3 � 10.5 |
hypertensive |
this finding was unexpected, and further studies might be |
the Kolmogorov–Smirnov test. To compare continuous |
GROUP |
patients with hypertension. J Int Med Res 2001; 29(4):270–279. |
5–10 mg/day), for 12 weeks immediately after baseline |
and cardiology outpatient clinics who had a newly diagnosed essential hypertension were included in the study. A |
effect of 12 weeks of antihypertensive therapy with valsartan on lipid parameters is shown in Table 3. |
BMI. Mean SBP and DBP were 156.05 � 9.3 and 92.3 |
associations and confirm their clinical relevance for macrovascular and microvascular morbidity and mortality. |
role of valsartan in lipid-lowering function. |
[29] Andrzejczak D, Gorska D, Czarnecka E. Influence of amlodipine |
[24] Ahaneku J, Taylor G, Agbedana E, Walker O, Salako L. Changes |
variables, independent samples t test or Mann–Whitney |
and diuretics (7) have negative effects on lipid metabolism, whereas calcium channel blockers, particularly |
93.8 � 8.7 |
2012. doi:10.3109/10641963.2012.681722. [Epub ahead of print]. |
cardiovascular disease independent of high-density lipoprotein |
.084 |
Clinical and Experimental Hypertension, 2013; 35(6): 449–453 |
prevention of cardiovascular disease (4,5). |
[7] Neutel J. Metabolic manifestations of low-dose diuretics. Am J |
Although the mechanisms behind the drug-caused dyslipidemia is still uncertain, it has been said that valsartan |
therapy on serum lipids. Ann Intern Med 1995; 122(2):133–141. |
effects of valsartan with placebo in patients with mild to |
levels and apolipoprotein A and B levels significantly in |
88.3 � 4.8 |
the |
5.0 � 0.94 |
Males/females |
angiotensin II receptor blocker (valsartan, 80–320 mg/ |
INTRODUCTION |
same assay. Fasting plasma glucose, total cholesterol |
of |
results of previous studies that examined the effects of |
antihypertensive |
Abbreviations: HDL – high density lipoprotein; LDL – low density |
RESULTS |
and LDL cholesterol levels in comparison to valsartan. |
[12] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the |
As a result, in the treatment of hypertension, prior |
(Prinzmetal’s angina and chronic stable angina pectoris), |
chair for 10 minutes, and then the systolic blood pressure |
Dis |
[28] Delsing DJM, Jukema JW, Wiel MAVD, Princen HMG. |
For personal use only. |
P |
on |
patients |
affect lipid metabolism but others are observed to have |
elevated lipids and hypertension (AVALON) trial, coadministration of amlodipine (5 mg) and atorvastatin |
these drugs are metabolically neutral and cause few lipoprotein alterations (24). In a previous study, significant |
after treatment were 157.2 � 10.0 and 127.0 � |
Hypertension 2006; 47(1):45–50. |
.914 |
(SBP) and diastolic blood pressure (DBP) were recorded |
BMI (kg/m2) |
In the amlodipine group, there was a significant |
be taken into consideration while prescribing antihypertensive drugs in patients with clear evidence of dyslipidemia. |
154.2 � 57.2 |
said that it might potentiate the antiatherosclerotic effect |
450 |
Pharmacol 1998; 31(4):576–580. |
Table 1. Demographics, anthropometrics, baseline characteristics, |
In an animal study, it was demonstrated that amlodipine treatment alone did not significantly reduce atherosclerotic lesion development, and in cotreatment, it was |
.804 |
(LPS)-induced |
For personal use only. |
affect bradykinin or prostaglandin metabolism like |
BP that is described as newly diagnosed essential hypertension aiming at the smaller time from the start point. |
[16] Kirk JK. Angiotensin-II receptor antagonists: their place in therapy. Am Fam Physician 1999; 59(11):3140–3148. |
Rajagopalan et al., the effects of valsartan and valsartanstatin combination were compared in hypertensive patients, |
100.0 |
Diastolic BP (mm Hg) |
for its positive or negative effects on the lipid profile. |
1:6–11. |
metabolic abnormalities—the role of insulin resistance and the |
BP – blood pressure; MCV – mean corpuscular volume, MPV mean platelet volume, WBC – white blood cell, HDL – high density |
Hypertensive patients, which constitute a group at high |
207.4 � 33.1 |
Clin Exp Hypertens Downloaded from informahealthcare.com by Nyu Medical Center on 10/16/14 |
Currently, even for patients on antihyperlipidemic drug |
[3] Hokanson J, Austin M. Plasma triglyceride level is a risk factor for |
of amlodipine was coadministered with 10 mg of atorvastatin, the LDL level was reduced than that with 10 mg of |
Systolic BP (mm Hg) |
on serum lipids, or at least it may show no imrovement, |
coefficient evaluated the degree of linear association |
Creatinine (mg/dL) |
were separated, and all plasma samples were run in the |
patients. The aim of the present study was to investigate |
measured before treatment and in the 12th week. None |
(amlodipine, |
the angiotensin II-receptor antagonist losartan in Japanese |
characterized by high TG levels (14,15). Our study |
on the lipid profile in patients with essential hypertension. |
MCV (fL) |
study by Preston et al., it was expressed that when 5 mg |
.005 |
End of preview. Expand
in Data Studio
- Downloads last month
- 10